Neuronetics sees FY26 revenue $160M-$166M, consensus $164.15M

Gross Margin: 47% to 49%; Operating Expenses: $100 million to $105 million, inclusive of approximately $8.5 million of non-cash stock-based compensation; Operating Cash Flow: $(13) million to $(17) million. The Company anticipates a reduction in operating expense in the second half of 2026 as a result of on-going efficiency initiatives and associated investments. By the fourth quarter of 2026, operating expenses are projected to be less than $100 million on an annualized basis. Operating cash flow is expected to improve significantly throughout the year, driven by revenue growth, cost reduction, and continued working capital improvements.